Literature DB >> 21769476

Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.

Imad Zalloum1, Nancy Hakooz, Tawfiq Arafat.   

Abstract

To relate the pharmacokinetics of orally administered lansoprazole in healthy adult Jordanian men with CYP2C19 polymorphisms and to determine the percentage of CYP2C19 polymorphism in Jordanian population and the allelic frequency of CYP2C19*2 and CYP2C19*3. A total of 78 healthy Jordanian volunteers were included in this study from three different bioequivalence studies, one of these studies which included 26 volunteers was done on lansoprazole. Genotyping for CYP2C19*1, CYP2C19*2, CYP2C19*3 was done for all 78 volunteers, the data of genotyping of all subjects used for screening the frequency of different genotypes and the allelic frequency of different polymorphisms in healthy Jordanian men, the pharmacokinetics and genotyping data for the study of lansoprazole was matched and compared to investigate presence of statistical differences in pharmacokinetic parameters. In Jordanian subjects, the allele frequencies of the CYP2C19*2 and CYP2C19*3 mutation were 0.16 and 0, respectively. The concentration-time curves in the two groups [homozygote extensive metabolizer (homEM, n = 19) and heterozygote extensive metabolizer (homEM, n = 7)] groups were fitted to a non-compartment model. In the homEM and in the hetEM groups, the main kinetic parameters were as follows: T(max) (2.1875 ± 0.777) and (2.54 ± 1.87) h, C(max) (697.875 ± 335) and (833.58 ± 436.26) mg/l, t(1/2) (1.3 ± 0.43) and (2.38 ± 1.64) h, AUC((0→∞)) were (1,684.9 ± 888) and (3,609.8 ± 318) mg h l(-1), respectively. The Jordanian population showed similarities in CYP2C19 allele and genotype distribution pattern with Caucasians and Africans. CYP2C19 allele and poor metabolizer (PM) genotype frequencies in the Jordanian population are distinct from populations' from East Asia such as Japanese and Koreans. Although lower pharmacokinetic parameters were found in homEM compared to hetEM but there was no significant difference between the two groups (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769476     DOI: 10.1007/s11033-011-1204-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

1.  Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers.

Authors:  H A Dugger; J D Carlson; W Henderson; G R Erdmann; S M Alam; R Dham
Journal:  Eur J Pharm Biopharm       Date:  2001-03       Impact factor: 5.571

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Celso H Oliveira; Rafael E Barrientos-Astigarraga; Eduardo Abib; Gustavo D Mendes; Débora R da Silva; Gilberto de Nucci
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-15       Impact factor: 3.205

Review 4.  Proton pump inhibitors and acid-related diseases.

Authors:  G Sachs
Journal:  Pharmacotherapy       Date:  1997 Jan-Feb       Impact factor: 4.705

5.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Prevalence of CYP2C19 polymorphisms in the Lebanese population.

Authors:  Isabelle Djaffar Jureidini; Nabil Chamseddine; Sose Keleshian; Rania Naoufal; Laila Zahed; Noha Hakime
Journal:  Mol Biol Rep       Date:  2011-03-05       Impact factor: 2.316

7.  Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.

Authors:  Toshihito Saitoh; Hiroko Otsuka; Takahiro Kawasaki; Hitoshi Endo; Daijirou Iga; Masahiko Tomimatsu; Yasushi Fukushima; Takao Katsube; Kenji Ogawa; Kuniaki Otsuka
Journal:  Hepatogastroenterology       Date:  2009 May-Jun

8.  Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations.

Authors:  S P Myrand; K Sekiguchi; M Z Man; X Lin; R-Y Tzeng; C-H Teng; B Hee; M Garrett; H Kikkawa; C-Y Lin; S M Eddy; J Dostalik; J Mount; J Azuma; Y Fujio; I-J Jang; S-G Shin; M R Bleavins; J A Williams; J D Paulauskis; K D Wilner
Journal:  Clin Pharmacol Ther       Date:  2008-03-19       Impact factor: 6.875

9.  CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.

Authors:  Abu-Eid I Sameer; Gharbieh M Amany; Abed A Abdela; Sharif A Fadel
Journal:  Can J Clin Pharmacol       Date:  2009-02-04

10.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Authors:  J A Goldstein; T Ishizaki; K Chiba; S M de Morais; D Bell; P M Krahn; D A Evans
Journal:  Pharmacogenetics       Date:  1997-02
View more
  10 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  A correlative study of polymorphisms of CYP2C19 and MDR1 C3435T with the pharmacokinetic profiles of lansoprazole and its main metabolites following single oral administration in healthy adult Chinese subjects.

Authors:  Chang-Yin Li; Jun Zhang; Ji-Hong Chu; Mei-Juan Xu; Wen-Zheng Ju; Fang Liu; Zou Jian-Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06       Impact factor: 2.441

3.  UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.

Authors:  Nancy Hakooz; Sameh Alzubiedi; Al-Motassem Yousef; Tawfiq Arafat; Rana Dajani; Nidaa Ababneh; Said Ismail
Journal:  Mol Biol Rep       Date:  2012-02-25       Impact factor: 2.316

4.  Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers.

Authors:  Hartley C Atkinson; Ioana Stanescu; Isam I Salem; Amanda L Potts; Brian J Anderson
Journal:  Eur J Clin Pharmacol       Date:  2014-12-06       Impact factor: 2.953

5.  In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Nathalie Bleyzac; Johanna Berry; Fannie Clavel-Grabit; Michel Tod
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 4.009

6.  Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.

Authors:  Can-Jun Ruan; Dong-Yang Liu; Ji Jiang; Pei Hu
Journal:  Eur J Clin Pharmacol       Date:  2012-05-15       Impact factor: 2.953

7.  A Decade of Pharmacogenetic Studies in Jordan: A Systemic Review.

Authors:  Alaa Yehya; Zaid Altaany
Journal:  Pharmacogenomics J       Date:  2021-04-13       Impact factor: 3.550

8.  ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel.

Authors:  Suheir Nassar; Omar Amro; Hilal Abu-Rmaileh; Inji Alshaer; May Korachi; Suhail Ayesh
Journal:  Meta Gene       Date:  2014-04-23

Review 9.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09

10.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.

Authors:  Su-Jun Lee
Journal:  Front Genet       Date:  2013-02-01       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.